OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu
OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu Detail:
Manufacturer with High Purity and Stable Quality
Commercial Supply Favipiravir (CAS: 259793-96-9) and Related Intermediates:
Favipiravir CAS: 259793-96-9
3,6-Dichloropyrazine-2-Carbonitrile CAS: 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS: 356783-28-3
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS: 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8
2-Aminopropanediamide CAS: 62009-47-6
Diethyl Aminomalonate Hydrochloride CAS: 13433-00-6
Chemical Name | Favipiravir |
Synonyms | T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide |
CAS Number | 259793-96-9 |
CAT Number | RF-API18 |
Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
Molecular Formula | C5H4FN3O2 |
Molecular Weight | 157.1 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Off-White Powder |
Identification | 1) IR 2) HPLC |
Melting Point | 188.0℃-193.0℃ |
Related Substances (Area Normalization) |
Any Single Impurity: ≤0.10% (HPLC) |
Total Impurities: ≤1.0% (HPLC) | |
Purity / Analysis Method | ≥99.0% (HPLC) |
Moisture (K.F) | ≤0.50% |
Residue on Ignition | ≤0.10% |
Heavy Metals | ≤20ppm |
Residue Solvents | |
Methanol | ≤3000ppm |
Ethyl Acetate | ≤5000ppm |
Isopropanol | ≤5000ppm |
Acetonitrile | ≤410ppm |
n-Heptane | ≤5000ppm |
Test Standard | Enterprise Standard |
Usage | Active Pharmaceutical Ingredient (API); Treatment of COVID-19 |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer’s requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19.
Favipiravir (T-705) is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.
Product detail pictures:
Related Product Guide:
Adhering for the theory of "quality, services, performance and growth", we have received trusts and praises from domestic and worldwide shopper for OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu , The product will supply to all over the world, such as: Naples, Frankfurt, Wellington, Should any of these items be of interest to you, please let us know. We'll be satisfied to give you a quotation upon receipt of one's detailed specifications. We have our personal experienced R&D enginners to meet any of one's requriements, We appear forward to receiving your enquires soon'and hope to have the opportunity to work together with you in the future. Welcome to check out our company.
By Bruno Cabrera from Accra - 2017.01.28 18:53
This company conforms to the market requirement and joins in the market competition by its high quality product, this is an enterprise that have Chinese spirit.
By Daniel Coppin from Mongolia - 2018.05.22 12:13